S&P 500 Gains, Crude Falls Ahead Of Fed's Expected First Hike Since 2023: Stock Market Today
Crude tumbles 3.6% on a Saudi pipeline restart, easing yields and lifting chips, while the Fed prepares its first rate hike in nearly three years.
Stocks · News reference
Moderna Advances Ebola Vaccine Into Human Testing
Moderna starts Phase 1 trials for Ebola vaccine mRNA-1469. See premarket MRNA stock reaction, analyst updates, and ETF exposure.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
QUICK SPARK: Amgen Stock Eyes Worst Day Since October 2000
Amgen sank 9.8% Tuesday after Novartis' pelacarsen missed its Phase 3 endpoint, casting doubt on rival Lp(a) drug olpasiran.
S&P 500, Nasdaq Slip as $98 Brent Reignites Inflation Fears: Stock Market Today
Crude near $98 pushes the 10-year Treasury yield above 4.8% for the first time since 2023, hammering the Dow as traders price a Fed rate hike next week.
What's Going On With Amgen Stock Tuesday?
AMGN stock dips 9% after rival drug trial misses goal. Discover Amgen key support levels, technical outlook, and analyst price targets
Is Cancer the Turnaround Moderna Has Been Looking for Post-COVID?
Moderna reported positive Phase III results for its personalized mRNA cancer therapy (intismeran autogene) developed with Merck, showing significant improvements in recurrence-free and distant metastasis-free survival in melanoma patients. The breakthrough validates Moderna's mRNA platform beyond vaccines and opens opportunities across multiple tumor types, while the company simultaneously expands its respiratory vaccine portfolio with RSV, flu, and combination vaccines to reduce COVID-19 dependence.
Moderna (MRNA) Ascends While Market Falls: Some Facts to Note
Moderna (MRNA) closed at $146.69, up 1.89%, outperforming the S&P 500 despite rising 127.37% in the past month. However, the company faces headwinds with expected EPS of -$1.36 (down 166.67% YoY) and revenue projected at $888.78 million (down 12.52% YoY). The stock holds a Zacks Rank #3 (Hold) rating with a modest 1.42% increase in consensus EPS estimates over 30 days.